Tests dapagliflozin or pioglitazone added to metformin and DPP-4 inhibitor in type 2 diabetes
Tests dapagliflozin or pioglitazone added to standard drugs in adults with type 2 diabetes.
Key facts
- Who runs it
- Dong Wha Pharmaceutical Co. Ltd.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 196 people, planned
- Started
- 28 May 2024
- Planned end
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DW6012(Dasidiem tab. 10/100mg)
- Record updated
- 17 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus a DPP-4 inhibitor.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes with HbA1c from 7.0% (53 mmol/mol) up to less than 10% (86 mmol/mol), and BMI up to 40 kg/m2
- Earlier treatment
- Must have taken a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks. Must not have used insulin, sulfonylurea, thiazolidinedione, SGLT2 inhibitor or GLP-1 receptor agonist in the 8 weeks before screening.
Main reasons for not taking part
- Type 1 diabetes
- Moderate or severe kidney disease (eGFR below 45 mL/min/1.73 m2), end stage kidney disease or dialysis
- Uncontrolled heart failure (NYHA class III - IV)
- History of ketoacidosis or metabolic acidosis
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Patients with type 2 diabetes who are 19 years of age or older at the date of written consent
- Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening
- HbA1c ≤ 7.0% ≤ HbA1c < 10% at time of screening
- BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening
- Subjects fully explained and understood the purpose and methods of this study and voluntarily gave written informed consent
Who cannot take part
- Patients with history of uncontrolled arrhythmia, myocardial infarction, unstable angina, coronary artery bypass graft surgery, cerebrovascular disease within 24 weeks prior to the screening visit
- Patients who receiving treatment for thyroid dysfunction at the time of screening
- Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit
- Patients who have received more than 2 consecutive weeks of corticosteroids within 8 weeks at the time of screening or who require treatment requiring repeated use of corticosteroids
- Participation in any other clinical trial within 12 weeks of screening in which an investigational drug or investigational medical device was administered or applied
- Patients with type 1 diabetes
- Patients with end stage renal disease or patients on dialysis
- Patients with uncontrolled heart failure (NYHA class III - IV)
- Patients with acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis (DKA) with or without coma, and patients with a history of ketoacidosis
- Patients with a history of severe hypoglycemia while taking metformin and DPP-4 inhibitors
- Patients with pituitary insufficiency or adrenal insufficiency
- Patients with severe infectious diseases, perioperative, or clinically significant trauma
- Have a history of substance abuse
- Patients with a history of malignancy within the last 5 years
- Hypersensitivity to any of the drugs and components, including metformin, DPP-4 inhibitors, dapagliflozin, TZDs, sulfonylurea class of drugs, or any of the ingredients
- Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) < 45 mL/min/1.73 m2
- Patients with clinically significant hepatic disease with AST or ALT greater than 3 times the upper limit of normal
- Patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose mal-absorption
- Have a BMI > 40 kg/m2
- Patients with diabetic coma or precoma
- Patients with hematuria
- Malnourished, starving, or debilitated subjects
- Pregnant and breastfeeding women
- Any other person deemed by the investigator to be unsuitable for participation in the study
Where in South Korea
- Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Kyung Hee University Hospital at GangdongTaking people
About the trial
What the trial wants to find out
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)
The 2 groups in the trial
- Dasidiem 10/100mgTreatment being tested
Dapagliflozin 10mg +sitagliptin 100mg combination drug
Treatment: DW6012(Dasidiem tab. 10/100mg)
- sitdiem 100mg, Piotazone15mgExisting treatment, for comparison
sitagliptin 100mg, Pioglitazone 15mg
Treatment: DW6012(Dasidiem tab. 10/100mg)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Key Finding of DM Treatment with Combination, a MuLticenter, Randomized, Parallel, Gathering Information of Phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone Add-on to Metformin and DPP-4 Inhibitor in Patients with Type 2 Diabetes
- Plain-language title
- Tests dapagliflozin or pioglitazone added to metformin and DPP-4 inhibitor in type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 March 2025